DelveInsight’s, “Neuromyelitis Optica Spectrum Disorder Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Neuromyelitis Optica Spectrum Disorder pipeline landscape. It covers the Neuromyelitis Optica Spectrum Disorder Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the Neuromyelitis Optica Spectrum Disorder Pipeline? Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight
Key Takeaways from the Neuromyelitis Optica Spectrum Disorder Pipeline Report
Want to know which companies are leading innovation in Neuromyelitis Optica Spectrum Disorder? Dive into the full pipeline insights @ Neuromyelitis Optica Spectrum Disorder Clinical Trials Assessment
The Neuromyelitis Optica Spectrum Disorder Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Neuromyelitis Optica Spectrum Disorder Pipeline Report also highlights the unmet needs with respect to the Neuromyelitis Optica Spectrum Disorder.
Neuromyelitis Optica Spectrum Disorder Overview
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare, severe autoimmune disease of the central nervous system in which the body’s immune system mistakenly attacks healthy cells in the optic nerves and spinal cord. This condition often leads to episodes of optic neuritis (causing eye pain and vision loss) and transverse myelitis (causing weakness, paralysis, sensory loss, and bladder or bowel dysfunction). Unlike multiple sclerosis, NMOSD is commonly associated with antibodies against aquaporin-4 (AQP4-IgG), which target water channel proteins on astrocytes, leading to inflammation and nerve damage.
Neuromyelitis Optica Spectrum Disorder Emerging Drugs Profile
BAT4406 is an investigational ADCC-enhanced anti-CD20 mAb candidate in clinical development for the treatment of autoimmune diseases. BAT4406F is currently being evaluated in NMOSD, an orphan indication with an estimated prevalence of 0.5 to 10 per 100,000. BAT4406 is a type I glyco-engineered mAb that binds specifically to CD20 on B-cells, kills the B-cells by CDC, and enhances ADCC effect. B cells have been implicated in the pathogenesis of a number of autoimmune diseases, including the CNS disorders, multiple sclerosis (MS) and NMOSD. Depletion of B-cells could provide meaningful relief for these autoimmune diseases. NMOSD is an autoimmune inflammatory disorder of the central nervous system (CNS) with preferential localization to the optic nerve, spinal cord and brain stem. Patients typically experience bouts of vision loss or blindness, attacks of myelitis with often severe motor impairment including loss of ambulation, sensory disturbances, bowel/bladder dysfunction, and brainstem attacks with characteristic episodes of intractable nausea, vomiting and hiccups. Currently, the drug is in Phase III stage of its development for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD).
B001 is a recombinant humanized anti‑CD20 monoclonal antibody developed by Shanghai Jiaolian Drug Research & Development (originating from Shanghai Pharmaceuticals Holding). It works by targeting CD20 on B cells and triggering antibody‑dependent cellular cytotoxicity (ADCC) to deplete autoreactive B cells, a mechanism aligned with current NMOSD treatment goals. Designed for intravenous administration, B001 aims to reduce disease relapses in AQP4‑IgG positive NMOSD through sustained B‑cell suppression. It also shows potential across other autoimmune neurologic conditions and B‑cell malignancies, illustrating a broad therapeutic strategy rooted in targeted immunotherapy. Currently, the drug is in Phase II/III stage of its development for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD).
Equecabtagene Autoleucel (Eque-cel) is an innovative fully human anti-BCMA CAR-T cell therapy which uses lentivirus as a gene vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane, and 4-1BB co-stimulatory and CD3ζactivation domains. Based on rigorous molecular structure screening and comprehensive in vitro and in vivo functional evaluations, Eque-cel demonstrates rapid and potent efficacy, accompanied by exceptional long-term persistence in vivo, enabling patients to achieve higher and deeper responses. Currently, the drug is in Phase I stage of its development for the treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD).
If you’re tracking ongoing Neuromyelitis Optica Spectrum Disorder Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Neuromyelitis Optica Spectrum Disorder Treatment Drugs
The Neuromyelitis Optica Spectrum Disorder Pipeline report provides insights into:-
Neuromyelitis Optica Spectrum Disorder Companies
Bio-Thera Solutions, Bioray Laboratories, Nanjing Bioheng Biotech Co., Ltd., Nanjing IASO Biotherapeutics, Shanghai Jiaolian Drug Research and Development Co. Ltd, Shanghai Xiniao Biotech Co., Ltd. and others.
Neuromyelitis Optica Spectrum Disorder Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
Neuromyelitis Optica Spectrum Disorder Products have been categorized under various Molecule types such as,
From emerging drug candidates to competitive intelligence, the Neuromyelitis Optica Spectrum Disorder Pipeline Report covers it all – check it out now @ Neuromyelitis Optica Spectrum Disorder Market Drivers and Barriers, and Future Perspectives
Scope of the Neuromyelitis Optica Spectrum Disorder Pipeline Report
Stay ahead in Healthcare Research – discover what’s next for the Neuromyelitis Optica Spectrum Disorder Treatment landscape in this detailed analysis @ Neuromyelitis Optica Spectrum Disorder Emerging Drugs and Major Players
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight
